S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com -- Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) reported second-quarter earnings that significantly exceeded analyst expectations, driving shares up 2.8% as investors responded positively to the company’s strong performance and upbeat outlook.
The pharmaceutical company posted adjusted earnings per share of $0.40 for the second quarter, dramatically surpassing the analyst consensus of $0.04. Revenue reached $2.53 billion, beating estimates of $2.48 billion and representing a 5% increase compared to $2.40 billion in the same quarter last year.
"In the second quarter, we achieved our ninth consecutive quarter of year-over-year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb," said Thomas J. Appio, Chief Executive Officer of Bausch Health. "This consistent performance highlights our operational excellence and the strength of our diverse portfolio across therapeutic areas and geographies."
The company’s Salix segment was a standout performer with 12% YoY growth to $627 million, driven primarily by its Xifaxan product, which saw 10% revenue growth. The Solta Medical (TASE:BLWV) segment also delivered impressive results with a 25% increase to $128 million.
Bausch Health raised its full-year 2025 guidance, now projecting revenue between $10 billion and $10.25 billion, compared to the analyst consensus of $10.037 billion. The company also increased its Adjusted EBITDA forecast to between $3.485 billion and $3.635 billion, representing growth of 3% to 7% over the prior year.
The company generated $289 million in cash from operating activities during the quarter, though this represented a 24% decrease from the $380 million generated in the second quarter of 2024.
Bausch Health continues to focus on strengthening its balance sheet and advancing its R&D pipeline, with several products in late-stage development including RED-C for hepatic encephalopathy, with Phase 3 results anticipated by early 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.